Edition:
United States

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

2.85USD
22 Jun 2018
Change (% chg)

$0.10 (+3.64%)
Prev Close
$2.75
Open
$2.75
Day's High
$2.85
Day's Low
$2.70
Volume
29,011
Avg. Vol
24,236
52-wk High
$3.95
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

TRACON Pharmaceuticals Announces $38.7 Million Private Placement
Friday, 23 Mar 2018 08:30am EDT 

March 23 (Reuters) - Tracon Pharmaceuticals Inc ::TRACON PHARMACEUTICALS ANNOUNCES $38.7 MILLION PRIVATE PLACEMENT.TRACON PHARMACEUTICALS - FINANCING LED BY PUISSANCE CAPITAL MANAGEMENT, PARTICIPATION FROM NEW ENTERPRISE ASSOCIATES, 683 CAPITAL PARTNERS, OTHERS.TRACON PHARMACEUTICALS -‍ EXPECTS TO APPOINT TED WANG, CHIEF INVESTMENT OFFICER OF PUISSANCE CAPITAL MANAGEMENT TO BOARD FOLLOWING CLOSE.TRACON PHARMACEUTICALS INC - ‍ TO USE PROCEEDS TO FUND DEVELOPMENT OF TRC105, TO CONTINUE DEVELOPMENT OF OTHER ASSETS SUCH AS TRC253​.  Full Article

TRACON Pharma Qtrly Loss Per Share $0.37
Wednesday, 28 Feb 2018 04:05pm EST 

Feb 28 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.THERE WAS NO COLLABORATION REVENUE FOR Q4 OF 2017 COMPARED TO $0.6 MILLION FOR Q4 OF 2016.QTRLY LOSS PER SHARE $0.37.Q4 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S.  Full Article

Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China
Thursday, 21 Dec 2017 06:55am EST 

Dec 21 (Reuters) - Tracon Pharmaceuticals Inc ::AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA.AMBRX INC - ENTERED INTO LICENSING AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION OF TRACON'S PROPRIETARY ENDOGLIN ANTIBODY, TRC105 IN CHINA.AMBRX SAYS TRANSACTION GRANTS AMBRX EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE TRC105 IN ALL INDICATIONS IN CHINA AND TAIWAN.AMBRX SAYS UNDER DEAL TERMS, TRACON WILL RECEIVE AN UPFRONT PAYMENT OF $3 MILLION.AMBRX SAYS TRACON IS ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES FROM HIGH SINGLE DIGITS TO LOW TEENS ON NET SALES OF TRC105 IN AMBRX TERRITORIES.  Full Article

Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Tracon Pharmaceuticals Inc ::Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget.Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​.Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity​.  Full Article

Tracon Pharma reports third quarter financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports third quarter financial results and provides corporate update.Tracon Pharmaceuticals Inc-qtrly ‍shr $0.07​.  Full Article

683 Capital Management reports 5.4 pct passive stake in Tracon Pharmaceuticals
Thursday, 28 Sep 2017 05:10pm EDT 

Sept 28 (Reuters) - Tracon Pharmaceuticals Inc :683 Capital Management Llc reports 5.4% passive stake in Tracon Pharmaceuticals Inc as of Sept 18, 2017 - SEC filing‍​.  Full Article

Tracon Pharmaceuticals files for offering of up to $14.33 mln of co's common stock‍​
Tuesday, 5 Sep 2017 06:07am EDT 

Sept 5 (Reuters) - Tracon Pharmaceuticals Inc :Files for offering of up to $14.33 million of co's common stock‍​ - SEC filing.  Full Article

Tracon Pharmaceuticals announces positive results for phase 1/2 trial of TRC105 and Nexavar
Wednesday, 16 Aug 2017 08:00am EDT 

Aug 16 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals announces positive results from National Cancer Institute Phase 1/2 trial of TRC105 and Nexavar in Hepatocellular cancer published in Clinical Cancer Research.Tracon Pharmaceuticals Inc - ‍NCI study researchers concluded that combination of TRC105 and Nexavar was well-tolerated​.Tracon Pharmaceuticals Inc - ‍We expect to report data from Tracon-sponsored multicenter phase 1/2 HCC trial in early 2018​.  Full Article

Tracon Pharmaceuticals qtrly net loss per share $0.40
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports second quarter financial results and provides corporate update.Qtrly net loss per share $0.40.Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Tracon Pharmaceuticals reports collaboration revenue $626,000
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports first quarter financial results and provides corporate update.Qtrly loss per share $0.44 collaboration revenue $626,000 versus $1.21 million.  Full Article

BRIEF-Tracon Pharmaceuticals Files For Offering Of Up To 27.4 Mln Shares Of Common Stock By The Selling Stockholders

* TRACON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 27.4 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS Source text: [https://bit.ly/2KQef7f] Further company coverage: